Systemic Activation of Macrophages by Liposomes Containing Muramyltripeptide Phosphatidylethanolamine for therapy of Cancer Metastasis

References

• Fidler I.J., Balch C.M. The biology of cancer metastasis and implications for therapy. Curr. Probl. Surg. 1987; 24: 131
   Google Scholar
• Fidler I.J., Poste G. The cellular heterogeneity of malignant neoplasms: Implications for adjuvant chemotherapy. Semin. Oncol. 1985; 12: 207
   PubMed Web of Science ®Google Scholar
• Nicolson G.L. Tumor cell instability, diversification and progression to the metastatic phenotype: From oncogenes to oncofetal expression. Cancer Res. 1987; 47: 1473
   PubMed Web of Science ®Google Scholar
• Fidler I.J. Macrophages and metastasis—a biological approach to cancer therapy: presidential address. Cancer Res. 1985; 45: 4714
   PubMed Web of Science ®Google Scholar
• Fidler I.J. Immunomodulation of macrophages for cancer and antiviral therapy. Site-Specific Drug Delivery, E. Tomlinson, S.S. Davis. John Wiley and Sons, New York 1986; 111
   Google Scholar
• Fidler I.J. Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv. Drug Deliv. Rev. 1988; 1: 69
   Google Scholar
• Fogler W.E., Fidler I.J. Modulation of the immune response by muramyl dipeptide. Immune Modulation Agents and their Mechanisms, M.A. Chirigos, R.L. Fenichel. Marcel Dekker, New York 1984; 499
   Google Scholar
• Fidler I.J. The MAF dilemma. Lymphokine Res. 1984; 3: 51
   Google Scholar
• Saiki I., Fidler I.J. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J. Immunol. 1985; 135: 684
   PubMed Web of Science ®Google Scholar
• Saiki I., Sone S., Fogler W.E., Kleinerman E.S., Lopez-Berestein G., Fidler I.J. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cancer Res. 1985; 45: 6188
   Google Scholar
• Fidler I.J., Fogler W.E., Kleinerman E.S., Saiki I. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human gamma interferon encapsulated in liposomes. J Immunol. 1985; 135: 4289
   PubMed Web of Science ®Google Scholar
• Poste G., Kirsh R., Fogler W.E., Fidler I.J. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res. 1979; 39: 881
   PubMed Web of Science ®Google Scholar
• Kleinerman E.S., Fogler W.E., Fidler I.J. Intracellular activation of human and rodent macrophages by human lymphokines encapsulated in liposomes. J. Leukocyte Biol. 1985; 37: 571
   Google Scholar
• Fidler I.J., Poste G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Semin. Immunopathol. 1982; 5: 161
   PubMed Web of Science ®Google Scholar
• Schroit A.J., Hart I.R., Madsen J., Fidler I.J. Selective delivery of drugs encapsulated in liposomes: natural targeting to macrophages involved in various disease states. J. Biol. Response Modif. 1983; 2: 97
   PubMedGoogle Scholar
• Schroit A.J., Fidler I.J. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 1982; 42: 161
   PubMed Web of Science ®Google Scholar
• Alving C.R. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol. ther. 1983; 22: 407
   PubMed Web of Science ®Google Scholar
• Poste G. Liposome targeting in vivo: problems and opportunities. Biol. Cell. 1983; 47: 19
   Web of Science ®Google Scholar
• Poste G., Kirsh R., Bugelski P. Liposomes as a drug delivery system in cancer therapy. Novel Approaches to Cancer Chemotherapy, P.S. Sunkara. Academic Press, New York 1984
   Google Scholar
• Fidler I.J., Raz A., Fogler W.E., Kirsh R., Bugelski P., Poste G. The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res. 1980; 40: 4460
   PubMed Web of Science ®Google Scholar
• Hart I.R., Fogler W.E., Poste G., Fidler I.J. Toxicity studies of liposome-encapsulated immunomodulators administered intravenously into dogs and mice. Cancer Immunol. Immunother. 1981; 10: 157
   Google Scholar
• Lopez-Berestein G., Mehta K., Mehta R., Juliano R.L., Hersh E.M. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J. Immunol. 1983; 130: 1500
   PubMedGoogle Scholar
• Poste G., Bucana C., Raz A., Bugelski P., Kirsh R., Fidler I.J. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 1982; 42: 1412
   PubMed Web of Science ®Google Scholar
• Fidler I.J. The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process. J Immunol. 1981; 127: 1719
   Google Scholar
• Fidler I.J. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science 1980; 208: 1469
   PubMed Web of Science ®Google Scholar
• Deodhar S.D., Barna B.P., Edinger M., Chiang T. Inhibition of lung metastases by liposomal immunotherapy in a murine fibrosarcoma. J. Biol. Response Modif. 1982; 1: 27
   Google Scholar
• Deodhar S.D., James K., Chiang T., Edinger M., Barna B. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human c-reactive protein. Cancer Res. 1982; 42: 5084
   Google Scholar
• Lopez-Berestein G., Milas L., Hunter N., Mehta K., Eppstein D., VanderPas M.A., Mathews T.R., Hersh E.M. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-0-steroyl-N-acetyl muramyl-L-amino-butyryl-D-isoglutamine. Clin. Exp. Metastasis 1984; 2: 366
   Google Scholar
• Phillips N.D., Mora M.L., Chedid L., Lefrancier P., Bernard J. Activation of tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 1985; 45: 128
   PubMed Web of Science ®Google Scholar
• Daemen T., Veninga A., Scherphof G.L., Roerdink F.H. The activation of Kupffer cells to tumor cytotoxicity with immunomodulators encapsulated in liposomes. Cells of the Hepatic Sinusoid, A. Kirn, D.L. Knook, E. Wisse. The Kupffer Cell Foundation, RijswijkThe Netherlands 1986; 379
   Google Scholar
• Eppstein D.A., VanderPas M.A., Fraser-Smith E.B., Kurahara C.G., Feigner P.L., Mathews T.R., Waters R.V., Venuti M.C., Jones G.H., Mehta R., Lopez-Berestein G. Liposome-encapsulated muramyl dipeptide analogue enhances non-specific host immunity. Int. J. Immunother. 1986; 2: 115
   Web of Science ®Google Scholar
• Thombre P., Deodhar S.D. Inhibition of liver metastasis in murine colon adenocarcinoma by liposomes containing human c-reactive protein or crude lymphokine. Cancer Immunol. Immunother. 1984; 16: 1984
   Google Scholar
• Talmadge J.E., Lenz B.F., Klabansky R., Simon R., Riggs C., Guo S., Oldham R.K., Fidler I.J. Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Cancer Res. 1986; 46: 1160
   PubMedGoogle Scholar
• MacEwen E.G., Kurzman I.D., Smith B.W., Rosenthal R.C. Therapy of metastasis in canine osteosarcoma. Liposomes in the therapy of Infectious Diseases and Cancer, G. Lopez-Berestein, I.J. Fidler. Alan R. Liss, New York 1989; 117
   Google Scholar
• Fidler I.J. Optimization and limitation of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol. Immunother. 1986; 21: 169
   Google Scholar
• Fidler I.J., Sone S., Fogler W.E., Barnes Z.L. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc. Natl. Acad. Sci. U.S.A. 1981; 78: 1680
   PubMed Web of Science ®Google Scholar
• Fidler I.J., Sone S., Fogler W.E., Smith D, Braun D.G., Tarcsay L., Gisler R.J., Schroit A.J. Efficacy of liposomes containing a lipophilic muramyl dipeptide for activating the tumoricidal properties of alveolar macrophages in vivo. J. Biol. Response Modif. 1982; 1: 43
   Google Scholar
• Fidler I.J., Barnes Z., Fogler W.E., Kirsh R., Bugelski P., Poste G. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res. 1982; 42: 496
   PubMed Web of Science ®Google Scholar
• Sone S., Fidler I.J. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J. Immunol. 1980; 125: 2454
   PubMedGoogle Scholar
• Fidler I.J., Schroit A.J. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastasis. J Immunol. 1984; 133: 515
   PubMedGoogle Scholar
• Fidler I.J., Fan D., Ichinose Y. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Invasion Metastasis 1989; 9: 75
   PubMedGoogle Scholar
• Hisano G., Fidler I.J. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin. Cancer Immunol. Immunother. 1982; 14: 61
   Google Scholar
• Kleinerman E.S., Hudson M.M. Liposome therapy: a novel approach to the treatment of childhood osteosarcoma. Liposomes in the Treatment of Infectious Diseases and Cancer, G. Lopez-Berestein, I.J. Fidler. Alan R. Liss, New York 1989; 71
   Google Scholar
• Saiki I., Milas I., Hunter N., Fidler I.J. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide. Cancer Res. 1986; 46: 4966
   PubMedGoogle Scholar